Ursula Matulonis, MD presented results of the SORAYA study at the 2022 Society for Gynecologic Oncology Annual Meeting. The study examined the efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression.
The trial that I presented at Sugo today is called the serious study. And this is a global single arm trial. Phase three study in patients with fr high or fr alpha high um platinum resistant ovarian cancer. So Mervat maximum syrup. Dancin is an antibody drug conjugate that's comprised of an fr alpha binding antibody, ACL Eva ble linker And the Mai Tan's annoyed DM four which is a potent turbulent targeting agent. The primary endpoint of this study was an investigator assessed overall response rate. These were confirmed objective responses and a key secondary endpoint was the duration of response. The eligibility of the trial where patients could receive have received at least one but up to three prior lines of chemotherapy, a platinum resistant ovarian cancer have received prior better system ab they could have received a prior apart inhibitor and their cancer cells on staining had to have high levels of fr alpha expression based upon the pathology test. The tax man. Mr Atkinson was given as a single agent at a dose of six mg per kilo intravenously every six weeks. And the sample size of this trial was about 105 patients. So the results were quite exciting. The confirmed investigator assessed objective response rate was 32.4%. We saw five Complete responses and 29 partial responses. The key secondary endpoint of duration of response was 6.9 months and both the overall response rate and duration of response was consistent regardless of the number of prior lines of treatment patients had previously received or prior receipt of apartment him bitter. The median progression free survival was 4.3 months, and the blinded Independent Central Review PFS was actually 5.5 months. So in summary these results position murder Taksim maps wrapped and seen as a practice changing biomarker driven treatment in patients with platinum resistant ovarian cancer, Who received up to three prior lines of treatment and whose cancers highly expressed FR alpha.
